Y.et al (2016)
Recent advances in neuroimaging technology allowing for in vivo quantification of GSH levels in the brain have shown decreased GSH in patients with MS compared to healthy controls, with the degree of depletion correlating with disease severity and showing parallel longitudinal decline over time (Mandal et al., 2015)
This chronic inflammation paradoxically fosters tumor growth, creating an ecosystem where immune escape is structurally embedded
Future studies will reveal the applicability of our model, for example, to activate enzymatically inactive glutaredoxins, to alter the sensitivity and responsiveness of glutaredoxin-coupled fluorescent redox sensors, to further address the catalytic mechanism with GSSCys, HEDS and physiological substrates, or to design specific transition-state inhibitors
Mandal A, Clegg JR, Anselmo AC, Mitragotri S (2020) Hydrogels in the clinic
& Garry, R